GlassScriptPhysician profile
Rushabh H Shah
NPI 1518290493
$2,785.36
in general payments reported to CMS, 2019-2025
12 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $113 · 2021: $267 · 2022: $405 · 2023: $417 · 2024: $364 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $546.15 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $465.92 | 2019-2022 | |
| Abiomed | $362.47 | 2019-2020 | |
| Lilly USA, LLC | $340.14 | 2022-2025 | Mounjaro |
| Abbvie INC. | $240.75 | 2024-2025 | |
| Novo Nordisk INC | $195.53 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $188.92 | 2022-2023 | Eliquis |
| Boston Scientific Corporation | $135.67 | 2025 | Axios |
| Pulmonx Corporation | $112.99 | 2019 | |
| Medtronic, INC. | $100.91 | 2024 | |
| Pfizer INC. | $73.79 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.12 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rushabh Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.